FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2041392157> ?p ?o ?g. }

• W2041392157 endingPage "955" @default.
• W2041392157 startingPage "947" @default.
• W2041392157 abstract "Protective antigen (PA) is a central component of anthrax toxin and a major antigen in anthrax vaccines. However, the use of native PA as a vaccine is not optimal. If administered to people who have been freshly exposed to anthrax, PA may actually aid in anthrax toxin formation and thus may pose a serious safety concern for postexposure vaccination applications. A non-functional PA mutant may be a much safer alternative. To identify an improved anthrax vaccine antigen, we examined four non-functional mutants of PA, each being impaired in a critical step of the cellular intoxication pathway of PA. These mutants were Rec− (unable to bind PA-receptors), SSSR (resistant to activation by furin), Oligo− (unable to form oligomers), and DNI (Dominant Negative Inhibitory, unable to form endosomal transmembrane pores). When tested in mice and after three doses of immunization, all four mutants were highly potent in eliciting PA-specific, toxin-neutralizing antibodies, with immunogenicity increasing in the order of PA < Rec− < SSSR < Oligo− < DNI. While the differences between Rec− or SSSR and PA were small and not statistically significant, DNI and Oligo− were significantly more immunogenic than wild-type PA. One year after immunization and compared with PA-immunized mice, DNI-immunized mice maintained significantly higher levels of anti-PA IgG with correspondingly higher titers of toxin-neutralizing activity. In contrast, Oligo−-immunized mice had high levels of anti-PA IgG but lower titers of toxin-neutralizing activity, suggesting that Oligo− mutation sites may overlap with critical protective epitopes of PA. Our study demonstrates that PA-based vaccines could be improved both in terms of safety and efficacy by strategic mutations that not only render PA non-functional but also simultaneously enhance its immunogenic potency. Recombinant PA mutants, particularly DNI, hold great promise as better and safer antigens than wild-type PA for use in postexposure vaccination." @default.
• W2041392157 created "2016-06-24" @default.
• W2041392157 creator A5022577551 @default.
• W2041392157 creator A5024064130 @default.
• W2041392157 creator A5041254024 @default.
• W2041392157 creator A5062473750 @default.
• W2041392157 date "2008-02-01" @default.
• W2041392157 modified "2023-10-18" @default.
• W2041392157 title "Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates" @default.
• W2041392157 cites W1827102232 @default.
• W2041392157 cites W1861465928 @default.
• W2041392157 cites W1974917488 @default.
• W2041392157 cites W1975952855 @default.
• W2041392157 cites W1979958088 @default.
• W2041392157 cites W1993096025 @default.
• W2041392157 cites W1995910871 @default.
• W2041392157 cites W2001064571 @default.
• W2041392157 cites W2001535873 @default.
• W2041392157 cites W2004673387 @default.
• W2041392157 cites W2004693684 @default.
• W2041392157 cites W2015148410 @default.
• W2041392157 cites W2042082935 @default.
• W2041392157 cites W2046957124 @default.
• W2041392157 cites W2055330678 @default.
• W2041392157 cites W2059734188 @default.
• W2041392157 cites W2074455992 @default.
• W2041392157 cites W2074490491 @default.
• W2041392157 cites W2075964433 @default.
• W2041392157 cites W2083766934 @default.
• W2041392157 cites W2097284735 @default.
• W2041392157 cites W2101852933 @default.
• W2041392157 cites W2107837037 @default.
• W2041392157 cites W2111443555 @default.
• W2041392157 cites W2129762741 @default.
• W2041392157 cites W2132058165 @default.
• W2041392157 cites W2135646101 @default.
• W2041392157 cites W2147070922 @default.
• W2041392157 cites W2158637618 @default.
• W2041392157 cites W2162178919 @default.
• W2041392157 cites W2163329733 @default.
• W2041392157 cites W2167872871 @default.
• W2041392157 cites W4229857880 @default.
• W2041392157 doi "https://doi.org/10.1016/j.vaccine.2007.11.087" @default.
• W2041392157 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2254513" @default.
• W2041392157 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18192092" @default.
• W2041392157 hasPublicationYear "2008" @default.
• W2041392157 type Work @default.
• W2041392157 sameAs 2041392157 @default.
• W2041392157 citedByCount "18" @default.
• W2041392157 countsByYear W20413921572013 @default.
• W2041392157 countsByYear W20413921572014 @default.
• W2041392157 countsByYear W20413921572015 @default.
• W2041392157 countsByYear W20413921572016 @default.
• W2041392157 countsByYear W20413921572018 @default.
• W2041392157 crossrefType "journal-article" @default.
• W2041392157 hasAuthorship W2041392157A5022577551 @default.
• W2041392157 hasAuthorship W2041392157A5024064130 @default.
• W2041392157 hasAuthorship W2041392157A5041254024 @default.
• W2041392157 hasAuthorship W2041392157A5062473750 @default.
• W2041392157 hasBestOaLocation W20413921572 @default.
• W2041392157 hasConcept C104317684 @default.
• W2041392157 hasConcept C123894998 @default.
• W2041392157 hasConcept C143065580 @default.
• W2041392157 hasConcept C147483822 @default.
• W2041392157 hasConcept C159047783 @default.
• W2041392157 hasConcept C159654299 @default.
• W2041392157 hasConcept C167508917 @default.
• W2041392157 hasConcept C181199279 @default.
• W2041392157 hasConcept C195616568 @default.
• W2041392157 hasConcept C203014093 @default.
• W2041392157 hasConcept C22070199 @default.
• W2041392157 hasConcept C2777265534 @default.
• W2041392157 hasConcept C2777289321 @default.
• W2041392157 hasConcept C2777351567 @default.
• W2041392157 hasConcept C2777367657 @default.
• W2041392157 hasConcept C2779261636 @default.
• W2041392157 hasConcept C2780239966 @default.
• W2041392157 hasConcept C2780801004 @default.
• W2041392157 hasConcept C2780868878 @default.
• W2041392157 hasConcept C32611913 @default.
• W2041392157 hasConcept C40767141 @default.
• W2041392157 hasConcept C41810244 @default.
• W2041392157 hasConcept C523546767 @default.
• W2041392157 hasConcept C54355233 @default.
• W2041392157 hasConcept C55493867 @default.
• W2041392157 hasConcept C86803240 @default.
• W2041392157 hasConcept C89423630 @default.
• W2041392157 hasConceptScore W2041392157C104317684 @default.
• W2041392157 hasConceptScore W2041392157C123894998 @default.
• W2041392157 hasConceptScore W2041392157C143065580 @default.
• W2041392157 hasConceptScore W2041392157C147483822 @default.
• W2041392157 hasConceptScore W2041392157C159047783 @default.
• W2041392157 hasConceptScore W2041392157C159654299 @default.
• W2041392157 hasConceptScore W2041392157C167508917 @default.
• W2041392157 hasConceptScore W2041392157C181199279 @default.
• W2041392157 hasConceptScore W2041392157C195616568 @default.
• W2041392157 hasConceptScore W2041392157C203014093 @default.
• W2041392157 hasConceptScore W2041392157C22070199 @default.

• next